clinicaladvisor.com

Dapagliflozin treats type 2 diabetes

Indication: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitation of use: not for treating type 1 diabetes mellitus or diabetic ketoacidosis.
PharmiWeb

Forxiga approved in the EU for heart failure

AstraZeneca’s Forxiga (dapagliflozin) has been approved in the European Union (EU) for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF) in adults with and ...
Business Wire

Data from contemporary registry confirms that four out of five patients with heart failure with reduced ejection fraction eligible for treatment with FARXIGA

DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) is an international, multi-center, parallel-group, randomized, double-blinded trial in 4,744 patients with heart failure and ...
Business Wire

FARXIGA reduced the incidence of heart failure worsening or cardiovascular death in a sub-analysis from landmark Phase III DAPA-HF trial

WILMINGTON, Del.--(BUSINESS WIRE)--New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial showed that AstraZeneca’s ...
FiercePharma

Forxiga™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes

Forxiga™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes Forxiga, a once-daily oral agent, provides ...
PMLiVE

AstraZeneca’s Farxiga scores another FDA fast-track designation

AstraZeneca’s heart failure drug Farxiga has picked up a US Food and Drug Administration (FDA) fast-track designation (FTD) in another indication as it continues to strengthen its position in an ...
pharmaphorum

FDA backs Glenmark's rival to AZ's blockbuster Farxiga

AstraZeneca’s diabetes drug Farxiga could face generic competition in the US, after the FDA gave tentative approval to a generic rival from India’s Glenmark, although it is unclear when the potential ...
FiercePharma

Forxiga Receives Regulatory Approval in Japan for the Treatment of Type 2 Diabetes

AstraZeneca today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved FORXIGA® (dapagliflozin in 5 and 10 mg tablets), a sodium-glucose cotransporter 2 (SGLT2) inhibitor ...
Pharmabiz

AstraZeneca’s Forxiga receives Japanese approval to treat chronic kidney disease in patients with and without type-2 diabetes

AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in Japan for the treatment of chronic kidney disease (CKD) in adults with and without ...
Yahoo Finance

AstraZeneca's Farxiga Gets CRL from FDA for Type I Diabetes

AstraZeneca AZN announced that the FDA has issued a complete response letter (“CRL”) to its supplemental new drug application (sNDA) for SGLT2 inhibitor, Farxiga (dapagliflozin). The sNDA sought ...
PharmiWeb

Forxiga approved in the EU for heart failure

with reduced ejection fraction in adult patients with and without type-2 diabetes AstraZeneca’s Forxiga (dapagliflozin) has been approved in the European Union (EU) for the treatment of symptomatic ...